Luminor Medical Technologies Inc (TSXV:LMT)
Luminor Medical Technologies Inc. is a TSX Venture Exchange listed medical diagnostic company based in Winnipeg, Canada. The company is focused on acquiring, developing, and commercializing non-invasive technologies for unmet clinical needs.
|10 Days Avg Vol||128,635.86|
|3 Mo Avg Vol||155,462.40|
|52 Wk Lo/Hi||$0.130 - $0.740|
|YTD Price Gain %||-100%|
|12 Wks Moving Avg||0.293944|
|200 Days Moving Avg||0.244900|
Updated: Market Close, 02/22/2018
Pre-diabetes is blamed for 2.2 million deaths annually – greater than the death toll from diabetes itself. Early detection is critical if mortality rates are going to be reduced. The World Health Organization is clear about it: “The starting point for living well with diabetes is an early diagnosis – the longer a person lives with undiagnosed and untreated diabetes, the worse their health outcomes are likely to be. Easy access to basic diagnostics, such as blood glucose testing, should, therefore, be available in primary health-care settings.” This is the mission of Luminor Medical Technologies (TSX: V.LMT). The first and primary product offering today is the Scout DS. Our Mission is to improve the lives of people with diabetes and pre-diabetes by successfully identifying, developing, maximizing, and commercializing innovative non-Invasive screening and diagnostics medical technologies.
- Restructured and capitalizing company for success.
- Accelerating negotiation with distributors and join venture partner in critical markets for Scout DS:
- China, and India have 750 million diabetes/pre-diabetes patients.
- Developing world 270 million suffer diabetes/pre-diabetes patients.
- USA over 86 million with pre-diabetes undiagnosed
- Acquisition pipeline building and opportunities emerging.
- $42 million in R&D with $15million in carry-forward losses.
- Medical sector for such technologies received high valuations
|Luminor Medical Technologies Inc.|
|Common Shares||9, 365,429|
|Common Stock Warrants||3,665745|
|Fully Diluted Shares||13,799,974|
|Board and Management Holdings||30%+|
|Share Trading Activity|
|3 month average daily volume(shares)||17,875 shares|
|52 week low/high ($/share)||$0.14/$0.75|
|Current Share Price (Date)||$0.40|
|Average Warrant Price||$0.29|
|Market Capitalization (I/O)||$3.87 million|
|Current liability - convertible debenture $150,000 at $0.20.Long Term Debt - $1.6M with $300,000 due on December 31, 2018; $400,000 due on December 31, 2019; $600,000 due on December 31, 2020; $300,000 due on December 31, 2021.|
Research / Products InformationThe Scout DS® is a ground-breaking new diabetes-screening device that uses visible light to detect and measure biomarkers present in the skin associated with pre-diabetes and type 2 diabetes. The SCOUT DS® is indicated for noninvasive screening of individuals 18 years or older who are at risk for prediabetes and/or type 2 diabetes to determine whether diagnostic testing is necessary. The process takes on average 90 seconds to complete. While offering equal reliability with conventional testing, the Scout DS® is faster, easier to use, and non-invasive (meaning no needles/ no blood required). In addition, there is no fasting requirement prior to testing.
President & CEO
Mr. Sauvageauas 30 years of experience in both the pharmaceutical and medical device fields.He has held senior sales, marketing, and business development positions with both national and international experience. >20 years at Merck Canada Ltd most recently as Vice President of customer innovation where he launched innovative products and practices. He led business units to $600 million in annual revenueMr. Sauvageau graduated with a B.Sc.(Biochemistry) from University Laval in Quebec, Canada and was an Officer of the Canadian Armed Forces. Christian combines a high degree of ethics and integrity to a passion for patient health and business results.
CEO Bradstone Capital Corp. a Canadian based merchant banking organization. Has 20 years providing financial reporting services for publicly traded companies on TSX, TSX Venture Exchange, CNSX and pre-public companies. Certified Accountant, graduated from Western University with B.A . (Business).As person with type 1 diabetes, Chris understands the challenges our target customer live on a daily basis.